Plus Therapeutics (PSTV) announced that it has signed an agreement to enter into a strategic partnership with Ephemeral Technologies to deliver an AI execution platform for CNS oncology. The AI execution platform is designed to integrate, organize, and derive actionable intelligence from longitudinal therapeutic, diagnostic and bioinformatic data sets generated across Plus’ CNS oncology technology programs.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PSTV:
- Plus Therapeutics Stockholders Back Directors and Incentive Plan
- Plus Therapeutics reports Q1 EPS ($1.05), consensus (87c)
- Plus Therapeutics Regains Nasdaq Listing Compliance After Reverse Split
- Plus Therapeutics regains compliance with Nasdaq minimum bid price requirement
- PSTV Upcoming Earnings Report: What to Expect?